News

A Leading Neurologist Joins Innodem Neurosciences

Innodem Neurosciences, a leader in digital health and the convergence of neuroscience, pharmaceuticals and AI, is proud to announce the appointment of a leading authority on neurodegenerative and mental diseases, Dr. Paul...

Read more
Innodem Neurosciences technology featured in Nature
Dr. Paul Giacomini Radio interview on CBC - Breakaway with Alison Brunette
Partnership effort leverages AI to help detect disease progression in multiple sclerosis
Innodem Neurosciences' ETNA™-MS obtains Health Canada's Approval
Canadian biomarker research: How could it improve the standard of care in MS?
A Leading Neurologist Joins Innodem Neurosciences
Innodem Neurosciences signs a strategic commercial framework agreement with Novartis Pharmaceuticals Canada Inc.
Oculomotor analysis to assess brain health: preliminary findings from a longitudinal study of multiple sclerosis using novel tablet-based eye-tracking software
A novel tablet-based software for the acquisition and analysis of gaze and eye movement parameters: a preliminary validation study in Parkinson’s disease
ETNA™ Device from Leading Digital Health & AI Company Innodem Neurosciences Receives FDA “Breakthrough” Designation for Multiple Sclerosis
Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.
Innodem Neurosciences receives 6 million US Dollars of financing from Morningside Group
Copyright © Innodem Neurosciences 2024 |